- Press releasesPress releases
- Events & ActivityEvents & Activity
- Can-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy
- Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update
- Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
- Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer
- Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
- Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
Can Fite Biopharma Ltd (CANF:TLV) closed at 300.10, 12.82% above the 52 week low of 266.00 set on Aug 09, 2017.
266.00Aug 09 2017549.00Sep 20 2016
|Market cap||100.50m ILS|
|EPS (TTM)||-1.05 |
Data delayed at least 20 minutes, as of Sep 19 2017 15:24 BST.